The FDA has authorized imports of cisplatin from China, as this crucial medication remains in short supply in the United States due to a halt in cisplatin production by the Indian manufacturer Intas Pharmaceuticals following a 2022 FDA inspection that raised concerns about the company’s manufacturing process.
The agency may allow imports for carboplatin, another chemotherapy medication facing a shortage.
While welcoming the new stock, American Society of Health-System Pharmacists (ASHP)